VACCINES AGAINST DENGUE VIRUS

Team Members

Dr. Nikole Warner

Susan Core

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for dengue virus vaccines.  We identify antigens of interest that are important for dengue virus infection and pathogenesis, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block dengue virus infection or key functions of the antigens.

​

Publications:

Warner NL, Linville AC, Core SB, Moreno B, Pascale JM, Peabody DS, Chackerian B, Frietze KM. 2020. Expansion and refinement of deep sequence-coupled biopanning technology for epitope-specific antibody responses in human serum. Viruses Sep 30;12(10):1114. doi: 10.3390/v12101114.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600589/

​

Funding:

NIH/NIAID R21 AI148836 to Kathryn M. Frietze

UNM School of Medicine RAC grant to Kathryn M. Frietze